在阿尔茨海默氏病中,微RNA-125a-3p通过MAPK途径调节粉样蛋白β蛋白
Xi-Chen Zhu1,2,3,4, Meng-Zhuo Zhu3, Jing Lu4
1Department of Neurology, the Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu Province, China.
Current Alzheimer research
|September 15, 2023
概括
微RNA 125a-3p通过调节粉样蛋白前体蛋白加工和Aβ代谢来影响阿尔茨海默病 (AD) 病理学. 准这种微RNA可能为AD提供未来的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 微RNA (miR)-125a-3p涉及到中枢神经系统疾病,包括阿尔茨海默病 (AD).
- 在AD病变发生过程中,miR-125a-3p的精确机制仍然未被阐明.
研究的目的:
- 研究miR-125a-3p在阿尔茨海默氏症病理过程中的作用和机制.
- 评估miR-125a-3p对AD相关细胞功能的影响.
主要方法:
- 在阿尔茨海默病队列中评估miR-125a-3p表达.
- 操纵miR-125a-3p水平以评估对细胞活力,细胞亡,粉样蛋白β (Aβ) 代谢和突触活性的影响.
- 确定了潜在的分子机制.
主要成果:
- miR-125a-3p调节了粉样蛋白前体蛋白加工和Aβ代谢.
- miR-125a-3p通过MAPK通路影响细胞存活和突触活动,涉及纤维细胞生长因子受体2.
- 通过miR-125a-3p对Aβ代谢的调节会影响突触的表达.
结论:
- miR-125a-3p在AD病理学中发挥着重要作用.
- 向miR-125a-3p为阿尔茨海默病提供了潜在的治疗途径.
- 需要进一步的体外和体内研究来验证这些发现.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
531
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.8K
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
